No Data
No Data
Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $35
Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet
Express News | Kiniksa Pharmaceuticals Ltd: Board Size Increases From Nine to Ten
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Delivers Shareholders Stellar 23% CAGR Over 5 Years, Surging 4.7% in the Last Week Alone
Kiniksa Draws Buy at Jefferies on Potential Blockbuster Status for Lead Drug
Jefferies Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $40
No Data
No Data